{"product_id":"passagebio-five-forces-analysis","title":"Passage Bio Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePassage Bio faces high competitive intensity driven by biotech incumbents and pipeline uncertainty, while supplier and buyer leverage vary with trial-stage partnerships and payer scrutiny; regulatory hurdles and substitute therapies add notable pressure. This brief snapshot only scratches the surface—unlock the full Porter's Five Forces Analysis to explore detailed force ratings, visuals, and strategic implications tailored to Passage Bio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized AAV manufacturing capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio depends on a handful of specialized CDMOs for high-quality AAV vectors; global AAV manufacturing capacity was estimated at ~200–300 clinical-grade batches\/year in 2024, so suppliers hold pricing and scheduling leverage as Passage scales trials through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property and licensing partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio depends on licensed capsids and delivery tech from the University of Pennsylvania\/Gene Therapy Program, giving those licensors strong bargaining power over royalties, field restrictions, and sublicensing; in 2025 Passage reported R\u0026amp;D spend of $145m, so licensing cost shifts materially affect cash burn.\u003c\/p\u003e\n\u003cp\u003eA licensor controlling modification or expansion rights can block or delay new indications, raising pipeline risk—any partnership change could jeopardize programs like PBGM01 and force costly renegotiations.\u003c\/p\u003e\n\u003cp\u003eGiven limited alternative IP—most AAV capsids are patented—supplier power remains high, implying sustained royalty and milestone liabilities and potential dilution if equity concessions are required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to high-grade biological reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe synthesis of Passage Bio's gene therapies depends on medical-grade plasmids and reagents made by a handful of specialized suppliers, and roughly 70–80% of clinical-grade plasmid capacity in 2024 was concentrated among top five vendors, raising single-source risk. Any supplier disruption can delay GMP manufacturing runs and push trial timelines by months, increasing development costs; Passage Bio reported R\u0026amp;D expense of $137.4M in 2024, so delays materially affect burn. This supplier concentration lets vendors set prices and lead times in a niche market, compressing margins and forcing Passage to secure long-term contracts or dual sourcing to reduce risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition for specialized scientific talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe pool of researchers and clinicians with dual expertise in gene therapy and CNS disorders is very small, driving up hiring costs; biotech hiring data show specialized gene-therapy scientist salaries rose ~12–18% YoY through 2024 and total compensation often exceeds $250k in hotspots like Boston and San Francisco.\u003c\/p\u003e\n\u003cp\u003eAs \u0026gt;150 new genomic-medicine startups entered the field by late 2025, competition pushed retention costs and contractor rates higher, raising operational spend and stretching R\u0026amp;D timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall talent pool = high supplier power\u003c\/li\u003e\n\u003cli\u003eSalaries up ~12–18% YoY; comp \u0026gt;$250k in hotspots\u003c\/li\u003e\n\u003cli\u003e150+ new startups by late 2025 increased demand\u003c\/li\u003e\n\u003cli\u003eHigher Opex and slower R\u0026amp;D cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial site and investigator availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConducting trials for rare CNS disorders needs specialized centers and highly trained principal investigators; only about 50–100 US sites (est. 2024) can handle complex intrathecal or intraparenchymal administrations, giving those sites strong leverage.\u003c\/p\u003e\n\u003cp\u003ePassage Bio must outbid larger pharma for site access, staff time, and scheduling; site contracting delays can add months and raise trial costs—site premiums of 10–30% over routine studies were reported in 2023.\u003c\/p\u003e\n\u003cp\u003eLimited site capacity plus competing programs increases supplier bargaining power, raising risk to timelines and requiring higher site incentives and strategic partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~50–100 specialized US sites (2024)\u003c\/li\u003e\n\u003cli\u003eSite premiums 10–30% (2023 data)\u003c\/li\u003e\n\u003cli\u003eCompetes with big pharma for investigators\u003c\/li\u003e\n\u003cli\u003eDelays add months, raise trial costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: limited AAV capacity, dominant plasmid vendors drive high Passage costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers—CDMOs, plasmid\/reagent makers, licensors (UPenn), specialized sites and talent—hold high bargaining power for Passage Bio; 2024–25 data: global AAV clinical capacity ~200–300 batches\/yr, top-5 plasmid vendors = 70–80% capacity, Passage R\u0026amp;D spend $137.4–145m, ~50–100 specialized US CNS sites, specialized scientist comp \u0026gt;$250k and +12–18% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eMetric (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal AAV capacity\u003c\/td\u003e\n\u003ctd\u003e~200–300 batches\/yr (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 plasmid share\u003c\/td\u003e\n\u003ctd\u003e70–80% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePassage R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$137.4–145M (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized US sites\u003c\/td\u003e\n\u003ctd\u003e~50–100 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist comp\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$250k; +12–18% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Passage Bio, this Porter's Five Forces overview uncovers competitive drivers, supplier and buyer influence, entry barriers, substitutes, and emerging threats shaping its market position and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Passage Bio Porter's Five Forces one-sheet that highlights competitive intensity and collaboration opportunities to speed therapeutic strategy decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated payer influence on pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers—mainly Medicare, Medicaid, and large private insurers—hold strong leverage over Passage Bio because they negotiate reimbursement for therapies that can cost $1–3M per dose; in 2024 US specialty drug spend was $250B, pushing payers to demand discounts and outcomes-based contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdoption of outcome-based payment models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValue-based contracts tying payments to multi-year clinical milestones are rising; 2024 CMS pilots and several US payers now seek outcomes links in rare-disease deals, shifting reimbursement risk to manufacturers and strengthening customer bargaining power. Passage Bio faces higher negotiation pressure as payers demand performance data for GM1 and Krabbe treatments, often with payment spread over 3–5 years and potential rebates of 20–40% if targets fail. This raises cash-flow and capital needs— Passage Bio must model 5–10 year revenue deferrals and secure financing to cover up-front manufacturing and trial costs. Negotiating warranties, data rights, and stop-loss clauses will be key to keep therapies economically viable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of rare disease advocacy groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient advocacy groups shape priorities and funding in rare diseases; for example, the National Organization for Rare Disorders (NORD) influenced policy that helped secure $1.1B for gene therapy R\u0026amp;D in 2024, steering Passage Bio toward high-impact indications.\u003c\/p\u003e\n\u003cp\u003eThese groups press for affordable access—campaigns have led to price negotiations cutting list prices by 20–40% in several orphan drug cases—so Passage Bio’s pricing and launch plans face strong public scrutiny.\u003c\/p\u003e\n\u003cp\u003eThe collective voice can sway payers and regulators; 72% of surveyed rare disease advocates in 2025 said they would actively oppose companies they view as exploitative, making advocacy alignment a commercial necessity for Passage Bio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited patient populations in niche markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpfor ultra-rare cns disorders global patient counts often number in the low hundreds each can represent millions lifetime revenue so treating physicians and referral centers hold outsized leverage over adoption of passage bio therapies.\u003e\u003cpif a major center adopts competitor protocol passage bio can lose large share of the addressable market quickly shifting care patients swing revenues by tens millions annually given list prices gene therapies near per patient.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow patient counts = high per-patient revenue impact\u003c\/li\u003e\n\u003cli\u003eMajor centers control referral flows and protocols\u003c\/li\u003e\n\u003cli\u003eLoss of 10–20 patients can cut revenues by $10–60M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pif\u003e\u003c\/pfor\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental regulatory and health technology assessments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGovernment health technology assessment (HTA) bodies—like NICE in the UK and IQWiG in Germany—act as gatekeepers, assessing cost-effectiveness and can exclude therapies from public formularies; in 2024, NICE rejected or recommended use only in research for ~12% of new high-cost therapies, showing real veto power.\u003c\/p\u003e\n\u003cp\u003eThis creates high-stakes entry risk for Passage Bio: a negative HTA decision can block an entire national market, sharply limiting peak sales and reimbursement prospects—HTA-driven price pressure often cuts target prices by 20–50% versus list price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHTA vetoes affect national access\u003c\/li\u003e\n\u003cli\u003eNICE ~12% rejection rate (2024)\u003c\/li\u003e\n\u003cli\u003ePrice cuts commonly 20–50%\u003c\/li\u003e\n\u003cli\u003eMarket entry depends on favorable cost-benefit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, HTAs \u0026amp; Advocacy Hold the Levers: Small Patient Shifts Risk $10–60M for Passage Bio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers, patient groups, centers, and HTAs wield strong leverage over Passage Bio—payers push outcomes-based deals (2024 US specialty drug spend $250B), advocacy influenced $1.1B gene therapy R\u0026amp;D (2024), NICE rejected ~12% high-cost therapies (2024), and losing 10–20 patients can swing $10–60M given $1–3M list prices.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStakeholder\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e$250B specialty spend (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\u003c\/td\u003e\n\u003ctd\u003e$1.1B R\u0026amp;D influence (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTA\u003c\/td\u003e\n\u003ctd\u003eNICE ~12% rejection (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCenters\u003c\/td\u003e\n\u003ctd\u003eLoss 10–20 pts = $10–60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePassage Bio Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Passage Bio Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the part of the full, professionally formatted report you’ll be able to download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final deliverable: the same comprehensive analysis file available instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747584094585,"sku":"passagebio-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/passagebio-five-forces-analysis.png?v=1772200090","url":"https:\/\/matrixbcg.com\/products\/passagebio-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}